Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

BMP10 inhibited the growth and migration of gastric cancer cells

Authors: Haiming Lei, Jian Wang, Peihua Lu, Xinghua Si, Koulan Han, Tingyan Ruan, Junjie Lu

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Bone morphogenetic protein 10 (BMP10), a novel member of BMP family, has been identified as an important regulator for angiogenesis. Dysregulation of BMP has been observed in several cancer types. However, its roles in gastric cancer (GC) remain unknown. In this study, the expression of BMP10 was found to be down-regulated in GC samples. Forced expression of BMP10 in GC cells inhibited its growth and migration, while knocking down the expression of BMP10 in GC cells promoted cell growth, migration, and metastasis. BMP10 was shown to negatively regulated beta-catenin/TCF signaling by up-regulating Axin protein level. Taken together, the present study revealed the suppressive function of BMP10 in gastric cancer.
Literature
1.
2.
3.
4.
Bazas VM, Lukyanova NY, Lisovenko GS, Rozumiy DO, Potebnya GP. Postoperative autovaccinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue. Exp Oncol. 2009;31:182–4.PubMed
5.
Schuetz JM, Leach S, Kaurah P, et al. Catenin family genes are not commonly mutated in hereditary diffuse gastric cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:2272–4.CrossRefPubMed
6.
Pan KF, Liu WG, Zhang L, You WC, Lu YY. Mutations in components of the wnt signaling pathway in gastric cancer. World J Gastroenterol. 2008;14:1570–4.CrossRefPubMedPubMedCentral
7.
8.
9.
Oshima H, Oguma K, Du YC, Oshima M. Prostaglandin e2, wnt, and bmp in gastric tumor mouse models. Cancer Sci. 2009;100:1779–85.CrossRefPubMed
10.
11.
12.
David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of bmp9 and bmp10 as functional activators of the orphan activin receptor-like kinase 1 (alk1) in endothelial cells. Blood. 2007;109:1953–61.CrossRefPubMed
13.
14.
Mazerbourg S, Hsueh AJ. Genomic analyses facilitate identification of receptors and signalling pathways for growth differentiation factor 9 and related orphan bone morphogenetic protein/growth differentiation factor ligands. Hum Reprod Update. 2006;12:373–83.CrossRefPubMed
15.
Zhang N, Ye L, Wu L, et al. Expression of bone morphogenetic protein-10 (bmp10) in human urothelial cancer of the bladder and its effects on the aggressiveness of bladder cancer cells in vitro. Anticancer Res. 2013;33:1917–25.PubMed
16.
Ye L, Bokobza S, Li J, et al. Bone morphogenetic protein-10 (bmp-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer. Cancer Sci. 2010;101:2137–44.CrossRefPubMed
17.
Kang MH, Oh SC, Lee HJ, et al. Metastatic function of bmp-2 in gastric cancer cells: the role of pi3k/akt, mapk, the nf-kappab pathway, and mmp-9 expression. Exp Cell Res. 2011;317:1746–62.CrossRefPubMed
18.
19.
Park Y, Kim JW, Kim DS, et al. The bone morphogenesis protein-2 (bmp-2) is associated with progression to metastatic disease in gastric cancer. Cancer Res Treat. 2008;40:127–32.CrossRefPubMedPubMedCentral
20.
Katoh M, Terada M. Overexpression of bone morphogenic protein (bmp)-4 mrna in gastric cancer cell lines of poorly differentiated type. J Gastroenterol. 1996;31:137–9.CrossRefPubMed
21.
Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. Bmp2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (pi3k)/akt pathway. Exp Cell Res. 2010;316:24–37.CrossRefPubMed
22.
Bertrand FE, Angus CW, Partis WJ, Sigounas G. Developmental pathways in colon cancer: Crosstalk between wnt, bmp, hedgehog and notch. Cell Cycle. 2012;11:4344–51.CrossRefPubMedPubMedCentral
23.
Villacorte M, Suzuki K, Hayashi K, et al. Antagonistic crosstalk of wnt/beta-catenin/bmp signaling within the apical ectodermal ridge (aer) regulates interdigit formation. Biochem Biophys Res Commun. 2010;391:1653–7.CrossRefPubMed
24.
Liu Z, Tang Y, Qiu T, Cao X, Clemens TL. A dishevelled-1/smad1 interaction couples wnt and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. J Biol Chem. 2006;281:17156–63.CrossRefPubMed
25.
Tian YC, Phillips AO. Interaction between the transforming growth factor-beta type ii receptor/smad pathway and beta-catenin during transforming growth factor-beta1-mediated adherens junction disassembly. Am J Pathol. 2002;160:1619–28.CrossRefPubMedPubMedCentral
Metadata
Title
BMP10 inhibited the growth and migration of gastric cancer cells
Authors
Haiming Lei
Jian Wang
Peihua Lu
Xinghua Si
Koulan Han
Tingyan Ruan
Junjie Lu
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4116-5

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

HNRNPC as a candidate biomarker for chemoresistance in gastric cancer

Original Article

Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer

Original Article

Low pretreatment serum globulin may predict favorable prognosis for gastric cancer patients

Original Article

Expression analysis of four long noncoding RNAs in breast cancer

Original Article

Downregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma

Original Article

Apoptotic effects of salinomycin on human ovarian cancer cell line (OVCAR-3)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits